Musculoskeletal

Lupus flares: organ-specific management

Clinical Overview and When to Suspect a Lupus Flare

— Female:male ~9:1; peak onset 15–44 years; disproportionate burden in Black, Hispanic, and Asian patients.

— Common triggers: UV exposure, infection, medication nonadherence (especially hydroxychloroquine), pregnancy/postpartum, sulfa drugs, estrogen surges, and psychosocial stress.

— New or worsening constitutional symptoms (fatigue, low-grade fever, weight loss) combined with organ-specific signs.

— Rising anti-dsDNA titers, falling C3/C4, new proteinuria, cytopenias, or arthralgia/rash recurrence.

— Always rule out infection first — fever in a lupus patient on immunosuppression is infection until proven otherwise.

— Mucocutaneous, musculoskeletal, serositis → typically mild–moderate flare.

— Lupus nephritis, CNS lupus, hemolytic anemia, severe thrombocytopenia, pulmonary hemorrhage, mesenteric vasculitis → severe flare requiring high-dose steroids ± induction immunosuppression.

Definition: A lupus flare is a measurable increase in SLE disease activity requiring change in therapy, distinct from chronic damage or drug toxicity. Validated tools include SLEDAI-2K, BILAG-2004, and the SELENA-SLEDAI Flare Index (mild/moderate vs severe).

Epidemiology and triggers:

When to suspect a flare in an established SLE patient:

Organ-specific patterns that drive Step 3 management decisions:

Step 3 management: The first ambulatory question is "Is hydroxychloroquine on board and being taken?" HCQ reduces flare frequency, organ damage, thrombosis, and mortality — it should be continued through nearly every flare unless retinopathy is documented.

Board pearl: A patient with SLE presenting with fever + low complement + rising dsDNA but normal procalcitonin favors flare; normal complement + high procalcitonin + leukocytosis favors infection. Both can coexist — culture and treat empirically while working up flare.

Presentation Patterns and Key History

— Malar (butterfly) rash sparing nasolabial folds, photosensitive; discoid lesions (scarring); subacute cutaneous LE (annular/psoriasiform, anti-Ro+).

— Painless oral/nasal ulcers (typically hard palate).

— Symmetric, non-erosive polyarthritis of small joints; Jaccoud arthropathy (reducible deformities, no erosions).

— Distinguish from overlap RA ("rhupus") which is erosive and anti-CCP+.

— Medication adherence, especially HCQ; sun exposure; recent infections, vaccinations, new drugs (procainamide, hydralazine, minocycline, TNF inhibitors → drug-induced lupus).

— Pregnancy status/contraception; estrogen exposure.

— Antiphospholipid syndrome features (clots, pregnancy loss).

Constitutional prodrome: Fatigue, malaise, low-grade fever, anorexia, lymphadenopathy — often precedes organ-specific manifestations by days to weeks.

Mucocutaneous flare:

Musculoskeletal flare:

Serositis: Pleuritic chest pain, dyspnea, pericardial rub; effusions are usually exudative with low glucose.

Renal flare (lupus nephritis): Often asymptomatic — detected by new proteinuria, hematuria with dysmorphic RBCs/casts, rising creatinine, hypertension, edema.

Neuropsychiatric SLE: Seizures, psychosis, cognitive dysfunction, stroke, mononeuritis multiplex, transverse myelitis, aseptic meningitis.

Hematologic flare: Autoimmune hemolytic anemia (Coombs+), immune thrombocytopenia, leukopenia/lymphopenia.

Cardiopulmonary: Myocarditis, Libman-Sacks endocarditis, diffuse alveolar hemorrhage (hemoptysis + dropping Hgb + new infiltrates — emergency).

Key history questions at every flare visit:

Key distinction: Drug-induced lupus spares kidneys and CNS, has anti-histone antibodies, and resolves with drug withdrawal — do not initiate immunosuppression; stop the offending agent.

Board pearl: New-onset psychosis in a young woman on prednisone — distinguish NPSLE (treat with more immunosuppression) from steroid psychosis (taper steroids). Anti-ribosomal P antibodies favor NPSLE.

Physical Exam Findings and Hemodynamic Assessment

— Document BP (lupus nephritis and steroids both drive hypertension), HR, temperature, SpO2, weight (volume status).

— Tachypnea + hypoxia in SLE → think alveolar hemorrhage, PE (APS!), pneumonitis, or pleural effusion.

— Inspect malar region, V of neck, extensor arms for photodistributed rash; scalp for discoid lesions and scarring alopecia; oral cavity (hard palate ulcers); nail folds for periungual erythema and dilated capillary loops.

— Livedo reticularis → suspect concurrent antiphospholipid syndrome.

— Pericardial friction rub, muffled heart sounds, pulsus paradoxus → tamponade (rare but emergent).

— Pleural rub, dullness, decreased breath sounds → effusion.

— New murmur → consider Libman-Sacks endocarditis (sterile verrucous valvular vegetations, often mitral).

— Full mental status exam, cranial nerves, motor/sensory, reflexes, gait.

— Focal deficits → stroke (consider APS-related), seizure focality; sensory level → transverse myelitis.

— Hypotension + tachycardia in lupus patient: think adrenal insufficiency (chronic steroids), sepsis, tamponade, hemorrhage, PE.

General/vitals:

Skin and mucosa:

Musculoskeletal: Symmetric small-joint synovitis (MCPs, PIPs, wrists) without erosive changes; tenosynovitis; reducible swan-neck/ulnar deviation (Jaccoud).

Cardiopulmonary:

Abdomen: Tenderness with rebound → mesenteric vasculitis or lupus enteritis (CT shows bowel wall thickening, "target sign," comb sign of engorged mesenteric vessels).

Neurologic:

Volume/renal exam: Periorbital and pedal edema, JVP, lung crackles — proteinuria + edema + HTN = nephritic/nephrotic flare.

Hemodynamic red flags driving disposition:

CCS pearl: In the CCS environment, order vitals q4h, daily weights, strict I/Os, and continuous pulse oximetry for any moderate-severe flare admission; recheck exam after each major intervention (steroid bolus, diuresis, transfusion).

Diagnostic Workup — Initial Labs, Imaging, and Biomarkers

— CBC with differential (cytopenias signal hematologic flare or marrow suppression from meds).

— CMP with creatinine and albumin; urinalysis with microscopy for casts; spot urine protein:creatinine ratio (UPCR) — single most important screen for lupus nephritis.

— ESR and CRP: ESR rises with flares; CRP disproportionately elevated suggests infection or serositis, not pure SLE activity.

— Anti-dsDNA — rising titer correlates with flare, especially renal.

— Complement C3, C4, CH50 — falling levels indicate active consumption.

— Anti-Smith (specific but doesn't track activity), anti-Ro/La (sicca, neonatal lupus), anti-RNP (overlap/MCTD), antiphospholipid panel (lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein I) if not previously documented or thrombotic event.

— CXR for serositis, pneumonitis, hemorrhage; echo for pericardial effusion, Libman-Sacks, pulmonary HTN.

— CT chest if alveolar hemorrhage suspected (ground-glass opacities), or PE workup (CTPA).

— MRI brain with contrast for NPSLE; LP to exclude infection and assess for pleocytosis/elevated IgG index.

Core flare panel (every visit):

Lupus-specific serologies:

Hematologic flare workup: Reticulocyte count, direct Coombs (DAT), haptoglobin, LDH, indirect bilirubin, peripheral smear (schistocytes suggest TTP/TMA, not classic SLE hemolysis).

Imaging:

Infection screen (always parallel to flare workup): Blood cultures, urine culture, CXR, procalcitonin, viral panels as indicated; screen for CMV, EBV, TB, hepatitis B/C, HIV before escalating immunosuppression.

Board pearl: Low C3/C4 + high anti-dsDNA + active urine sediment is the classic triad of lupus nephritis flare; biopsy is required to determine ISN/RPS class and guide therapy.

Step 3 management: Always order UPCR at every SLE visit — proteinuria is the earliest detectable sign of renal flare and changes therapy.

Diagnostic Workup — Advanced and Confirmatory Studies

— Indications: New proteinuria ≥0.5 g/day (UPCR ≥0.5), unexplained rise in creatinine, active urinary sediment, or to distinguish flare from chronic damage/thrombotic microangiopathy.

— ISN/RPS classification:

— Class I/II (minimal mesangial / mesangial proliferative): supportive care, no immunosuppression beyond HCQ.

— Class III/IV (focal/diffuse proliferative): induction with high-dose steroids + mycophenolate or cyclophosphamide ± belimumab or voclosporin.

— Class V (membranous): treat if nephrotic-range proteinuria; MMF preferred.

— Class VI (advanced sclerosis): supportive; prepare for renal replacement.

— MRI brain with/without contrast (white matter lesions, infarcts), MRA/MRV for vasculopathy/CVT.

— CSF: Mild pleocytosis, elevated protein, sometimes elevated IgG index/oligoclonal bands; primary purpose is to exclude CNS infection (especially in immunosuppressed: cryptococcus, listeria, HSV, PML/JC virus).

— EEG for suspected seizures; neuropsych testing for cognitive complaints.

— TTE → TEE if Libman-Sacks suspected.

— Bronchoscopy with BAL showing progressively bloodier returns confirms diffuse alveolar hemorrhage.

— Right heart catheterization if pulmonary hypertension on echo.

— Quantiferon-TB, HBV (HBsAg, anti-HBc, anti-HBs), HCV, HIV, VZV serology, pregnancy test, baseline ophthalmologic exam for HCQ.

Renal biopsy — the cornerstone of lupus nephritis management:

Skin biopsy: Lupus band test (IgG/C3 at dermoepidermal junction) when diagnosis uncertain; not routinely needed in known SLE.

NPSLE workup:

Cardiopulmonary advanced:

APS confirmation: Repeat antiphospholipid antibodies ≥12 weeks apart to confirm persistent positivity (requirement for diagnosis).

Pre-immunosuppression baseline:

Key distinction: TMA in lupus (Coombs-negative MAHA + thrombocytopenia + AKI) may represent catastrophic APS, TTP (check ADAMTS13), or atypical HUS — management diverges sharply (plasma exchange ± anticoagulation ± eculizumab), so smear and ADAMTS13 are mandatory.

Risk Stratification and First-Line Management Logic

— Mild flare: Constitutional symptoms, mild arthritis, limited rash, stable labs. SELENA-SLEDAI increase <3.

— Moderate flare: Significant arthritis, extensive rash, serositis, mild cytopenias, SLEDAI increase 3–12.

— Severe flare: Major organ involvement — nephritis, NPSLE, hemolytic anemia (Hgb <8 or transfusion-dependent), platelets <30k, alveolar hemorrhage, mesenteric vasculitis, myocarditis. SLEDAI increase >12.

— Mild: Optimize HCQ (5 mg/kg/day, max), topical steroids for rash, NSAIDs for arthritis/serositis (cautious — renal/GI), short low-dose prednisone (≤7.5 mg/day) if needed.

— Moderate: Prednisone 0.3–0.5 mg/kg/day with rapid taper, add methotrexate, azathioprine, or mycophenolate as steroid-sparing; consider belimumab for persistent activity despite standard therapy.

— Severe: IV methylprednisolone pulse 500–1000 mg daily × 3 days, then prednisone 0.5–1 mg/kg/day taper, plus induction immunosuppression (cyclophosphamide or MMF) ± rituximab for refractory cases.

— Continue HCQ unless contraindicated.

— Sun protection (broad-spectrum SPF ≥50, hats, clothing).

— Vaccinations updated before immunosuppression (influenza, pneumococcal, HPV, COVID, avoid live vaccines on immunosuppression).

— Cardiovascular and bone health: statin if indicated, calcium/vitamin D, DEXA, BP and lipid control.

Severity-stratified flare framework (EULAR/ACR 2023 update):

Treatment ladder by severity:

The "treat-to-target" goal: Lupus Low Disease Activity State (LLDAS) or remission, on prednisone ≤5 mg/day with HCQ + stable immunosuppression — minimizes damage accrual.

Universal measures regardless of severity:

Step 3 management: When starting steroids ≥7.5 mg prednisone equivalent expected for ≥3 months, initiate bisphosphonate + calcium/vitamin D and PJP prophylaxis with TMP-SMX when prednisone ≥20 mg/day for ≥4 weeks or combined with another immunosuppressant.

Pharmacotherapy — First-Line Drug Regimens by Organ System

— Dose ≤5 mg/kg actual body weight/day to minimize retinopathy.

— Baseline + annual ophthalmologic exam with OCT/visual fields after 5 years (or sooner with risk factors: CKD, tamoxifen, dose >5 mg/kg).

— Reduces flares ~50%, lowers thrombosis, improves lipids, increases survival.

— Lowest effective dose, shortest duration; target prednisone ≤5 mg/day as maintenance.

— Severe flare: methylprednisolone 500–1000 mg IV × 3 days, then oral taper.

— Lupus nephritis (Class III/IV): Induction = MMF 2–3 g/day OR low-dose IV cyclophosphamide (Euro-Lupus 500 mg q2wk × 6); combine with steroids and consider belimumab or voclosporin add-on. Maintenance = MMF or azathioprine for ≥3–5 years.

— Membranous (Class V) with nephrotic proteinuria: MMF + steroids; calcineurin inhibitors (tacrolimus, voclosporin) effective.

— NPSLE (inflammatory): Pulse methylprednisolone + cyclophosphamide; rituximab if refractory. For thrombotic NPSLE → anticoagulation.

— Hematologic (severe ITP, AIHA): Steroids first-line; rituximab, IVIG, MMF, azathioprine, or splenectomy for refractory.

— Skin/joints: Methotrexate, HCQ, topical tacrolimus; anifrolumab (anti-type I IFN receptor) for refractory non-renal SLE.

— NSAIDs: arthritis/serositis — avoid in nephritis, monitor BP/renal.

— ACEi/ARB for any proteinuria ≥0.5 g/day; SGLT2 inhibitor (dapagliflozin) increasingly added for proteinuric lupus nephritis.

— Anticoagulation (warfarin INR 2–3) for thrombotic APS; aspirin for primary prevention in high-risk aPL profile.

Hydroxychloroquine (foundation for ALL SLE patients):

Glucocorticoids:

Immunosuppressants by organ:

Adjuncts:

Board pearl: Mycophenolate is teratogenic (Category D) — must be stopped ≥6 weeks before conception and replaced with azathioprine, hydroxychloroquine, and/or tacrolimus (all pregnancy-compatible).

Expanded Pharmacology — Biologics, Refractory Disease, and Drug Pitfalls

— FDA-approved for active SLE and lupus nephritis as add-on; reduces flares and steroid burden.

— IV (10 mg/kg q4wk) or SC weekly; avoid in severe NPSLE (limited data).

— Approved for moderate-to-severe non-renal SLE; effective for skin and joint disease refractory to standard therapy.

— Increased risk of herpes zoster — give recombinant zoster vaccine before initiation.

— Off-label but commonly used for refractory hematologic SLE, NPSLE, and proliferative nephritis not responding to MMF/cyclophosphamide.

— Screen and treat HBV before infusion (risk of reactivation); monitor for PML.

— Approved for lupus nephritis in combination with MMF + steroids; rapid proteinuria reduction.

— Monitor BP and creatinine; fewer metabolic effects than cyclosporine.

— High-dose NIH protocol (500–1000 mg/m² monthly × 6) — more toxicity, used in severe disease/Black/Hispanic patients with historically lower response to Euro-Lupus.

— Euro-Lupus (500 mg IV q2wk × 6) — lower cumulative dose, preferred in White European populations.

— Mesna + hydration to prevent hemorrhagic cystitis; GnRH agonist (leuprolide) for ovarian protection in premenopausal women.

— Azathioprine + allopurinol/febuxostat → life-threatening myelosuppression (check TPMT/NUDT15 before starting AZA).

— MMF + iron, antacids, cholestyramine → reduced absorption.

— NSAIDs + ACEi + diuretic → "triple whammy" AKI in lupus nephritis.

— Sulfa antibiotics (TMP-SMX) can trigger flares but remain first-line for PJP prophylaxis — monitor.

Belimumab (anti-BLyS monoclonal):

Anifrolumab (anti–type I IFN receptor):

Rituximab (anti-CD20):

Voclosporin (calcineurin inhibitor):

Cyclophosphamide regimens:

Drug interactions and pitfalls:

CCS pearl: Before any biologic or cyclophosphamide order, advance the clock to complete TB screen, HBV/HCV/HIV, pregnancy test, vaccinations, and baseline CBC/CMP — CCS scoring rewards appropriate pre-therapy workup.

Special Populations — Elderly and Renal/Hepatic Impairment

— More serositis, pulmonary involvement, sicca, and neuropathy; less nephritis, malar rash, and Raynaud.

— Often milder serologic activity but higher damage accrual from comorbidities and steroid toxicity.

— Distinguish from drug-induced lupus (hydralazine, procainamide, isoniazid, minocycline, anti-TNF, PD-1 inhibitors) — anti-histone+, anti-dsDNA usually negative, normal complement.

— HCQ: No dose adjustment for CKD but higher retinopathy risk — reduce to 200 mg/day if eGFR <30, more frequent ophthalmology screening.

— NSAIDs: Avoid in eGFR <30 and active nephritis.

— MMF: No dose change but monitor for cytopenias; reduce dose if leukopenia.

— Cyclophosphamide: Reduce dose 25–50% in CKD; ensure aggressive hydration; avoid if eGFR <25 in some regimens.

— Methotrexate: Contraindicated if CrCl <30; reduce dose for CrCl 30–60.

— ACEi/ARB: First-line for proteinuria; monitor K+ and creatinine after initiation.

— Azathioprine, MMF, methotrexate all hepatotoxic — baseline and serial LFTs.

— Rule out autoimmune hepatitis overlap in SLE with transaminitis (smooth muscle, LKM antibodies).

— Screen and treat HBV before any immunosuppression; consider entecavir or tenofovir prophylaxis with rituximab or high-dose steroids in HBcAb+ patients.

— Elderly lupus patients have markedly elevated cardiovascular risk — aggressive lipid (statin), BP (<130/80), and glucose control.

— Osteoporosis prevention mandatory with chronic steroids: bisphosphonate or denosumab, calcium 1200 mg + vitamin D 800–1000 IU; baseline and serial DEXA.

Late-onset SLE (>50 years at diagnosis):

Renal impairment considerations:

Hepatic impairment:

Comorbidity-driven adjustments:

Step 3 management: In an elderly SLE patient on chronic prednisone presenting with confusion and hyponatremia, consider adrenal insufficiency from HPA suppression — give stress-dose hydrocortisone 100 mg IV while working up, rather than abruptly stopping/adjusting their steroid.

Special Populations — Pregnancy and Pediatrics

— Defer conception until SLE quiescent for ≥6 months; flares (especially nephritis) markedly increase pregnancy loss, preeclampsia, preterm birth, IUGR.

— Switch teratogenic drugs: stop MMF, methotrexate, cyclophosphamide, leflunomide, warfarin, ACEi/ARB. Replace with HCQ (continue!), azathioprine ≤2 mg/kg/day, tacrolimus, prednisone (lowest dose), low-molecular-weight heparin if APS.

— Continue HCQ throughout pregnancy and lactation — reduces flares, congenital heart block, and neonatal lupus.

— Low-dose aspirin 81–162 mg starting before 16 weeks for preeclampsia prevention in all SLE pregnancies.

— Anti-Ro/SSA positive: Risk of neonatal lupus with congenital complete heart block (~2%, up to 18% if prior affected child); fetal echo weekly from 16–26 weeks, then biweekly to 34 weeks. HCQ reduces recurrence.

— APS with prior thrombosis: therapeutic LMWH + low-dose aspirin through pregnancy and 6 weeks postpartum.

— Both have hypertension and proteinuria.

— Flare: Active urinary sediment (cellular casts), low C3/C4, rising anti-dsDNA, normal uric acid, occurs any trimester.

— Preeclampsia: Rising uric acid, elevated transaminases, normal complement, after 20 weeks, thrombocytopenia with hemolysis (HELLP).

— More severe at presentation: higher rates of nephritis (60–80%), NPSLE, cytopenias.

— Same drugs as adults with weight-based dosing; aggressive early immunosuppression.

— Growth, puberty, school performance, and bone health require longitudinal monitoring; minimize steroid exposure.

— Transition-of-care to adult rheumatology should be structured between ages 18–21 with shared appointments.

Pre-pregnancy planning is mandatory:

Pregnancy management:

Distinguishing flare from preeclampsia:

Pediatric SLE (cSLE):

Board pearl: A neonate with congenital complete heart block and a rash — check maternal anti-Ro and anti-La; mother may be asymptomatic at delivery but is at risk for future SLE/Sjögren — refer for rheumatology follow-up.

Complications and Adverse Outcomes

— End-stage renal disease: 10–30% of proliferative lupus nephritis progress to ESRD within 10 years; predictors include Black race, delayed therapy, high chronicity index on biopsy, persistent proteinuria.

— Accelerated atherosclerosis: SLE patients have a 50-fold increased MI risk in young women (35–44); driven by chronic inflammation, steroids, dyslipidemia, hypertension, nephritis.

— Thrombosis: APS-related arterial/venous events; pulmonary embolism; catastrophic APS (multi-organ thrombosis, >50% mortality).

— Avascular necrosis of femoral head from high-dose steroids — MRI hip for new hip/groin pain.

— Damage accrual (SLICC/ACR Damage Index): irreversible organ damage from disease and treatment.

— Infection — leading cause of death in early SLE; opportunistic (PJP, CMV, fungal, TB reactivation, JC virus/PML), encapsulated organisms post-splenectomy.

— Steroid toxicity: Cushingoid features, diabetes, hypertension, osteoporosis, cataracts, glaucoma, AVN, myopathy, psychiatric effects.

— Cyclophosphamide: Hemorrhagic cystitis, bladder cancer, infertility, myelosuppression, secondary malignancy.

— HCQ retinopathy: Bull's-eye maculopathy, irreversible — risk rises after 5 years, with CKD, with doses >5 mg/kg.

— MMF: GI intolerance, cytopenias, teratogenicity.

— Early deaths (<5 years): active disease, infection.

— Late deaths (>10 years): cardiovascular disease, malignancy, ESRD.

Disease-related complications:

Treatment-related complications:

Malignancy: Increased risk of non-Hodgkin lymphoma, lung cancer, cervical (HPV), and hepatobiliary cancers; reduced breast/prostate cancer risk.

Reproductive: Premature ovarian failure from cyclophosphamide — counsel on fertility preservation (oocyte/embryo cryopreservation, GnRH agonist co-treatment).

Mortality bimodal pattern:

Key distinction: New AKI in a stable SLE patient on chronic NSAIDs and ACEi — NSAID-induced AIN or hemodynamic AKI can mimic nephritis; check urine eosinophils, FENa, and recent medication changes before assuming flare and escalating immunosuppression.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Diffuse alveolar hemorrhage: hypoxia, dropping Hgb, infiltrates → intubation often required; pulse steroids + cyclophosphamide ± plasmapheresis ± rituximab.

— Catastrophic antiphospholipid syndrome (CAPS): Multi-organ thrombosis in <1 week → anticoagulation + steroids + plasmapheresis/IVIG ± rituximab/eculizumab.

— Severe NPSLE: Status epilepticus, coma, acute psychosis with safety risk, transverse myelitis with ascending deficits.

— TMA/TTP overlap: ADAMTS13 <10% → urgent plasma exchange.

— Severe hematologic crisis: Platelets <10k with bleeding, Hgb <6 with hemodynamic instability.

— Lupus myocarditis with heart failure or arrhythmia; pericardial tamponade.

— Mesenteric vasculitis with peritonitis or perforation risk.

— New severe flare requiring IV pulse steroids and induction immunosuppression.

— New nephritis with rapidly rising creatinine or nephrotic syndrome.

— Active infection requiring IV antibiotics on immunosuppression.

— Need for renal biopsy when outpatient not feasible.

— Same-day rheumatology for moderate flare; urgent ophthalmology for new visual symptoms.

— Nephrology for new proteinuria ≥0.5 g/day or rising creatinine.

— Rheumatology — quarterback for all flares.

— Nephrology for biopsy decisions, dialysis planning.

— Hematology for refractory cytopenias, APS management.

— Neurology/Psychiatry for NPSLE.

— Maternal-Fetal Medicine for SLE in pregnancy.

— Ophthalmology for baseline/annual HCQ screening.

ICU-level indications:

Inpatient admission (non-ICU):

Outpatient escalation:

Consult choreography:

CCS pearl: When admitting a lupus flare, simultaneously order rheumatology consult, infectious workup (cultures, CXR), pulse methylprednisolone if severe, GI/PJP prophylaxis, DVT prophylaxis (or therapeutic anticoagulation if APS), and stress-dose steroids if on chronic prednisone. Re-examine and recheck labs at appropriate intervals — CCS scoring rewards reassessment.

Key Differentials — Other Rheumatologic and Autoimmune Causes

— High-titer anti-U1-RNP, Raynaud, swollen hands, arthritis, myositis, pulmonary hypertension.

— Distinguish from SLE by prominent anti-RNP without anti-Sm or anti-dsDNA, and less renal/CNS disease.

— Sicca symptoms, anti-Ro/La; can overlap with SLE.

— Higher risk of MALT lymphoma; less aggressive systemic disease unless overlap.

— Erosive symmetric polyarthritis, anti-CCP positive, RF+; SLE arthritis is non-erosive.

— Skin thickening (sclerodactyly), telangiectasias, calcinosis, esophageal dysmotility, anti-centromere or anti-Scl-70/topoisomerase I, anti-RNA polymerase III (scleroderma renal crisis).

— Quotidian fevers, evanescent salmon-pink rash, arthritis, ferritin >5x ULN, hyperleukocytosis; ANA usually negative.

— Pulmonary-renal syndrome can mimic SLE; c-ANCA/PR3 or p-ANCA/MPO positive, low complement uncommon, anti-dsDNA negative.

— Thrombosis and pregnancy loss without SLE criteria; may evolve into SLE.

— Multiorgan fibroinflammatory lesions, elevated IgG4, characteristic histopathology (storiform fibrosis).

— Proximal weakness, elevated CK, characteristic rashes (heliotrope, Gottron); can overlap with SLE.

— Palpable purpura, neuropathy, glomerulonephritis, hepatitis C association, low C4 with normal C3 (vs SLE: both low).

Mixed connective tissue disease (MCTD):

Sjögren syndrome:

Rheumatoid arthritis ("rhupus"):

Systemic sclerosis:

Adult-onset Still disease:

ANCA-associated vasculitis (GPA, MPA, EGPA):

Antiphospholipid syndrome (primary):

IgG4-related disease:

Dermatomyositis/polymyositis:

Cryoglobulinemic vasculitis:

Key distinction: Low complement differential in adult glomerulonephritis = SLE, post-strep GN, MPGN (often hep C/cryoglobulinemia), endocarditis, shunt nephritis, atheroembolic disease. SLE has the active urinary sediment + anti-dsDNA + characteristic biopsy with full-house immunofluorescence (IgG, IgA, IgM, C3, C1q).

Key Differentials — Infectious, Drug-Induced, and Other Mimics

— Parvovirus B19: Symmetric polyarthritis, malar-like rash, cytopenias, transient ANA positivity — check B19 IgM/PCR before initiating immunosuppression in new-onset "lupus."

— EBV, CMV, acute HIV: Fevers, lymphadenopathy, cytopenias, autoimmune phenomena.

— Endocarditis: Fevers, low complement, glomerulonephritis, splinter hemorrhages — blood cultures and TEE before steroids.

— Tuberculosis (extrapulmonary): Constitutional symptoms, serositis — always rule out before biologics/steroids in high-risk patients.

— Disseminated gonococcal infection: Tenosynovitis, dermatitis, polyarthritis in young women.

— Classic offenders: procainamide, hydralazine, isoniazid, minocycline, quinidine, chlorpromazine, methyldopa.

— Newer: TNF inhibitors (infliximab, etanercept), interferons, immune checkpoint inhibitors (ipilimumab, nivolumab).

— Features: arthralgia, serositis, fever; spares kidney and CNS; anti-histone+ (95%); anti-dsDNA usually negative; normal complement.

— Resolves within weeks–months of stopping the drug.

— TTP: MAHA, thrombocytopenia, neurologic symptoms, fever, AKI — ADAMTS13 <10%; treat with plasma exchange, not immunosuppression alone.

— Atypical HUS, DIC, HIT: distinct treatments.

— Evans syndrome: AIHA + ITP — can be primary or SLE-associated.

— Macrophage activation syndrome (MAS) in lupus: high ferritin (>10,000), cytopenias, hypertriglyceridemia, hypofibrinogenemia, hepatosplenomegaly — treat with high-dose steroids ± anakinra ± etoposide.

— Thyroid disease: Hashimoto/Graves can produce fatigue, arthralgias, ANA positivity.

— Fibromyalgia overlay: Common in SLE; fatigue and diffuse pain without inflammatory markers or organ involvement — do not escalate immunosuppression.

Infections that mimic lupus flare:

Drug-induced lupus (DIL):

Hematologic mimics:

Other autoimmune-mimicking conditions:

Step 3 management: Before attributing new symptoms in an SLE patient to flare, always exclude infection with cultures, CXR, urinalysis, and procalcitonin; consider parvovirus, EBV, and CMV serologies. Empiric antibiotics + flare therapy may be necessary while workup pending.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Hydroxychloroquine ≤5 mg/kg/day — lifelong unless retinopathy.

— Prednisone taper plan written explicitly (e.g., 40 mg × 2 weeks, then decrease by 5 mg every 1–2 weeks to ≤5 mg/day).

— Steroid-sparing agent for any flare requiring >5 mg/day prednisone for >3 months: MMF, azathioprine, methotrexate, or belimumab.

— ACEi or ARB for any proteinuria; SGLT2 inhibitor for proteinuric lupus nephritis (dapagliflozin per DAPA-CKD).

— Aspirin 81 mg for high-risk aPL profile or established cardiovascular disease; statin per ASCVD risk (lower threshold in SLE given inflammatory risk).

— TMP-SMX for PJP on prednisone ≥20 mg/day ≥4 weeks plus another immunosuppressant.

— HBV prophylaxis (entecavir/tenofovir) for HBcAb+ patients on rituximab or high-dose steroids.

— Vaccinations (off active immunosuppression flare): annual influenza, pneumococcal (PCV20 or PCV15→PPSV23), Tdap, HPV, recombinant zoster ≥18 yrs on immunosuppression, hepatitis B, COVID-19. Avoid live vaccines (MMR, varicella, intranasal flu, yellow fever) on biologics or prednisone ≥20 mg/day.

— Calcium 1000–1200 mg/day, vitamin D 800–1000 IU/day.

— Bisphosphonate if prednisone ≥7.5 mg/day for ≥3 months, plus FRAX-based risk; denosumab as alternative.

— Baseline + 1–2 year DEXA.

— BP <130/80; LDL targeting per ASCVD risk; counsel smoking cessation (smoking worsens skin disease, reduces HCQ efficacy).

— Aggressive diabetes screening annually on steroids.

— Contraception: progestin-only or copper IUD preferred; combined OCPs only if SLE quiescent and aPL negative.

— Document preconception plan and medication compatibility.

Foundational discharge regimen after a flare:

Infection prophylaxis:

Bone health:

Cardiovascular and metabolic:

Reproductive health:

Key distinction: Secondary prevention in SLE is cardiovascular medicine — these patients die of MI and stroke more than active lupus. Treat lipids and BP aggressively even in young women.

Follow-Up, Monitoring Parameters, and Counseling

— Active flare: Every 2–4 weeks until stable, then every 1–3 months.

— Quiescent disease: Every 3–6 months.

— Lupus nephritis induction: monthly labs for 6 months minimum.

— CBC, CMP, urinalysis with microscopy, UPCR, anti-dsDNA, C3/C4, ESR/CRP.

— Drug-specific monitoring:

— MMF, azathioprine, methotrexate: CBC and LFTs every 2–4 weeks initially, then every 8–12 weeks.

— HCQ: Annual eye exam after 5 years (or baseline if risk factors).

— Cyclophosphamide: CBC weekly during induction, urinalysis for hematuria.

— Belimumab/anifrolumab/rituximab: Monitor for infusion reactions, infections, hypogammaglobulinemia.

— Use SLEDAI-2K or SLE-DAS at each visit to track activity.

— Document damage with SLICC/ACR Damage Index annually.

— Cervical cancer: annual Pap + HPV (more frequent on immunosuppression).

— Mammography, colonoscopy, lung cancer screening (LDCT) per age and smoking history.

— Skin cancer surveillance — sun-protective behavior reinforced.

— Sun protection (SPF ≥50, broad-spectrum, hats, UPF clothing).

— Medication adherence — single most modifiable predictor of flares.

— Pregnancy planning at every visit in reproductive-age women.

— Mental health screening — depression and anxiety prevalent in SLE; screen with PHQ-9, GAD-7.

— Fatigue management — sleep hygiene, graded exercise, treat anemia/thyroid/vitamin D.

Visit cadence:

Routine monitoring labs at each visit:

Disease activity assessment:

Cancer screening (often missed in immunosuppressed):

Counseling priorities:

Patient-reported outcomes: Lupus Quality of Life (LupusQoL), fatigue scales — incorporate into longitudinal care.

Step 3 management: At every SLE visit, document HCQ adherence, sun protection, contraception status, BP, UPCR, and complement/dsDNA. Missing these on a stem usually signals the answer to "next best step in management."

Ethical, Legal, and Patient Safety Considerations

— Must explicitly discuss infertility risk (especially women >30 yrs with cumulative dose >7.5 g), secondary malignancy (bladder, leukemia), hemorrhagic cystitis, infection.

— Offer and document fertility preservation referral (oocyte/embryo cryopreservation, GnRH agonist co-therapy) before initiating therapy — failure to do so is a recurring malpractice theme.

— Counsel all reproductive-age women with SLE on contraception and the teratogenicity of MMF, methotrexate, cyclophosphamide, warfarin, ACEi/ARB.

— Document medication-pregnancy discussion at each visit; respect patient autonomy if pregnancy is desired despite risk — coordinate with MFM and switch to compatible regimens preconception.

— Hospital discharge is a high-risk handoff: provide explicit prednisone taper schedule, immunosuppressant dosing, prophylactic medications, follow-up appointments with rheumatology within 1–2 weeks, and lab orders.

— Pediatric-to-adult transition in cSLE — structured between ages 18–21 with shared visits, written transfer summary, and confirmation of established adult rheumatology care before pediatric discharge. Lost-to-follow-up after transition is a recognized cause of flares and ESRD.

— Active TB, HIV, syphilis, hepatitis B/C — report per state law if newly diagnosed during pre-immunosuppression workup.

— Suspected child abuse if a pediatric SLE patient presents with injuries inconsistent with history.

— Document stress-dose steroid plan for any patient on chronic prednisone — MedicAlert bracelet, emergency hydrocortisone instructions, sick-day rules.

— Falls risk in elderly on steroids and antihypertensives — counsel on home safety.

— Black, Hispanic, and Asian patients have higher SLE incidence, severity, and mortality — ensure access to specialty care, biologics, and medication assistance programs; address insurance barriers proactively.

Informed consent for cyclophosphamide:

Pregnancy and reproductive autonomy:

Transitions of care:

Mandatory reporting and public health:

Steroid-related safety:

Health equity:

Board pearl: A 28-year-old woman with proliferative lupus nephritis declines cyclophosphamide due to fertility concerns — the ethically and clinically correct response is to offer MMF as an equivalent first-line induction agent and refer to reproductive endocrinology, not to coerce or withhold treatment.

High-Yield Associations and Rapid-Fire Clinical Facts

— Anti-dsDNA → nephritis, disease activity.

— Anti-Sm → specific for SLE (not sensitive).

— Anti-Ro/SSA, anti-La/SSB → neonatal lupus, congenital heart block, subacute cutaneous LE, Sjögren overlap.

— Anti-RNP → MCTD, Raynaud, myositis.

— Anti-ribosomal P → NPSLE (psychosis, depression).

— Anti-histone → drug-induced lupus.

— Antiphospholipid antibodies → thrombosis, pregnancy loss, livedo, thrombocytopenia.

— Anti-C1q → strongly associated with proliferative lupus nephritis.

— Low C3 + low C4 = classical pathway activation (SLE flare, MPGN type 1).

— Isolated low C4 = hereditary deficiency (predisposes to SLE), cryoglobulinemia.

— C1q, C2, C4 deficiencies → strong SLE predisposition.

— Malar rash: spares nasolabial folds (distinguishes from rosacea, seborrheic dermatitis, dermatomyositis heliotrope).

— Discoid: scarring, hyperpigmentation, follicular plugging.

— Subacute cutaneous: annular or psoriasiform, photodistributed, anti-Ro+.

Antibody-clinical correlations:

Complement patterns:

Renal biopsy classes (ISN/RPS): I minimal mesangial, II mesangial proliferative, III focal, IV diffuse, V membranous, VI advanced sclerosis.

Skin findings:

High-yield triggers: Sunlight (UVA/UVB), sulfa drugs, estrogen, infection, pregnancy/postpartum, medication nonadherence.

Catastrophic APS criteria: ≥3 organs involved within 1 week, biopsy-confirmed microthrombosis, persistent aPL.

HCQ retinopathy risk factors: dose >5 mg/kg/day, duration >5 years, CKD, tamoxifen use, preexisting retinal disease.

Mortality: Bimodal — early from infection/active disease; late from cardiovascular disease.

Key distinction: CRP is typically normal or mildly elevated in pure SLE flare (except serositis); markedly elevated CRP suggests infection, MAS, or serositis. ESR rises with flares but is nonspecific.

Board Question Stem Patterns

— 26-year-old woman with SLE on HCQ presents with new lower-extremity edema, BP 158/96, creatinine 1.6 (baseline 0.8), UPCR 3.2, active urinary sediment, low C3/C4, rising anti-dsDNA.

— Answer: Renal biopsy, then induction with MMF or cyclophosphamide + high-dose steroids; add ACEi.

— SLE patient on MMF and prednisone 10 mg with fever, cough, WBC 14k, procalcitonin elevated, normal complement, stable dsDNA.

— Answer: Infection — blood cultures, CXR, empiric antibiotics; do NOT escalate immunosuppression.

— 65-year-old man on hydralazine and procainamide with arthralgias, pleuritis, anti-histone+, normal complement, anti-dsDNA negative.

— Answer: Stop the offending agent; NSAIDs or short steroids if symptomatic.

— SLE woman on MMF wants to conceive in 6 months.

— Answer: Switch MMF to azathioprine or tacrolimus at least 6 weeks before conception; continue HCQ; add low-dose aspirin <16 weeks.

— Anti-Ro+ pregnant patient at 22 weeks.

— Answer: Continue HCQ, serial fetal echos for heart block surveillance from 16–26 weeks.

— SLE/APS patient with stroke, AKI, livedo, thrombocytopenia, multi-organ failure within days.

— Answer: Anticoagulation + pulse steroids + plasma exchange/IVIG; ICU.

— Patient started on high-dose prednisone develops paranoid delusions.

— Answer: Distinguish — if disease active (low C3, high dsDNA, anti-ribosomal P), treat as NPSLE with more immunosuppression; if labs quiescent, taper steroids.

— Asymptomatic SLE patient on HCQ for 6 years asks about screening.

— Answer: Annual ophthalmology with OCT and visual fields; lifestyle counseling; cardiovascular risk optimization.

Stem 1 — The classic nephritis flare:

Stem 2 — Flare vs infection:

Stem 3 — Drug-induced lupus:

Stem 4 — Pregnancy planning:

Stem 5 — Anti-Ro positive pregnancy:

Stem 6 — Catastrophic APS:

Stem 7 — NPSLE vs steroid psychosis:

Stem 8 — Routine maintenance question:

CCS pearl: The CCS exam will reward ordering HCQ continuation, ophthalmology screening, sun protection counseling, and pregnancy/contraception discussion alongside flare-specific therapy — these "background" orders score points beyond the acute intervention.

One-Line Recap

Lupus flares are managed by severity and organ system: continue hydroxychloroquine universally, use the lowest effective steroid dose with rapid steroid-sparing transition, and tailor induction immunosuppression (MMF, cyclophosphamide, belimumab, anifrolumab, rituximab, voclosporin) to the specific organ involved while aggressively addressing infection risk, cardiovascular prevention, bone health, and reproductive planning.

— Mild → topical/NSAIDs/low-dose steroids.

— Moderate → prednisone 0.3–0.5 mg/kg + MTX/AZA/MMF ± belimumab.

— Severe (nephritis, NPSLE, alveolar hemorrhage, severe cytopenias) → IV methylprednisolone pulse + MMF or cyclophosphamide ± rituximab/belimumab/anifrolumab.

Foundation: HCQ ≤5 mg/kg/day for every SLE patient — reduces flares, thrombosis, damage, and mortality; annual ophthalmology after 5 years.

Severity drives therapy:

Always rule out infection before escalating immunosuppression; CRP elevation, procalcitonin, and cultures help distinguish.

Lupus nephritis demands biopsy for ISN/RPS class, then class-directed induction + maintenance; add ACEi/ARB and consider SGLT2 inhibitor; target proteinuria <0.5–0.7 g/day.

Pregnancy planning is part of every visit: stop MMF/MTX/cyclophosphamide/warfarin/ACEi ≥6 weeks pre-conception; continue HCQ; add low-dose aspirin; fetal echo if anti-Ro+.

Cardiovascular disease is the leading late cause of death — treat BP <130/80, statin per risk, smoking cessation, weight, glucose control.

Prophylaxis on immunosuppression: PJP (TMP-SMX), bisphosphonate + Ca/Vit D, HBV prophylaxis if HBcAb+, vaccines updated (no live vaccines on biologics).

Board pearl: When stuck on any SLE management question, ask in order — Is HCQ on? Is infection excluded? What organ is flaring? What's the pregnancy plan? Is steroid taper and steroid-sparing agent in place? — these five anchors usually reveal the correct answer.